Arcola Laboratories

Arcola Laboratories is a specialty pharmaceutical subsidiary of Acrux, focused on the development and commercialization of topical and transdermal drug delivery products. The company utilizes proprietary MDTS (Multi-Dose Transdermal System) technology to deliver small molecule therapeutics through the skin. Arcola's primary asset, Axiron (testosterone topical solution), was a significant commercial success through a global licensing agreement with Eli Lilly. The company currently supports Acrux's broader strategy of developing a pipeline of high-value generic topical medicines. Arcola serves as the primary entity for holding US intellectual property and regulatory filings for the parent organization.